ROCKVILLE, Md., Aug. 12, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing
novel anti-infective biologic and drug programs targeting specific
pathogens that cause serious infections and diseases, announced
today that its SYN-005 for the treatment of Pertussis will be
highlighted at the 54th Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.
Synthetic Biologics' academic collaborator, Jennifer Maynard, Ph.D., of The University of Texas at Austin's McKetta Department
of Chemical Engineering will present Synthetic Biologics' SYN-005
monoclonal antibody (mAb) combination for the treatment of
Pertussis in an oral presentation scheduled for Sunday, September 7, at 9:45am Eastern Time in Room 209A as part of the
"Neonatal Infections and the Case for Maternal Immunization"
session.
Title: Rational Design of Antibody Cocktails to Treat Disease
Caused by Bordetellae
Authors: M. Kaleko1, A.
Nguyen2, E. Wagner2, J. Laber2, L.
Goodfield3, W. Smallridge3, E. T. Harvill3, R. F. Wolf4, J. C. Papin4, J. A. Maynard2
"We are pleased to have Dr. Maynard showcase the research
supporting the clinical development of SYN-005 amongst esteemed
academic peers, and the infectious disease field's foremost leaders
at ICAAC, a conference with high academic standards and commitment
to providing an overview of the state of infection control and
prevention on a global scale," stated Jeffrey Riley, Chief Executive Officer of
Synthetic Biologics. "This scientific presentation is timely, as we
continue to advance our innovative Pertussis program toward
clinical-stage development in early 2015."
1Synthetic Biologics, Rockville, MD, 2Universty of
Texas at Austin, Austin,
TX, 3Penn State Univ., University Park, PA, 4Univ. of
Oklahoma Hlth. Sci. Ctr., Oklahoma City,
OK
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral biologic
to protect the gastrointestinal microflora from the effects of IV
antibiotics for the prevention of Clostridium difficile (C.
difficile) infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS), a series of monoclonal antibodies for the
treatment of Pertussis and Acinetobacter infections, and a
biologic targeted at the prevention and treatment of a root cause
of a subset of IBS. In addition, the Company is developing an oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding Synthetic Biologics'
continued advancement of its Pertussis program toward
clinical-stage development. The forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from those reflected in
Synthetic Biologics' forward-looking statements include, among
others, the additional clinical studies and results not meeting
expectations and other factors described in Synthetic Biologics'
report on Form 10-K for the year ended December 31, 2013 and any other filings with the
SEC. The information in this release is provided only as of the
date of this release, and Synthetic Biologics undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.